Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
100.00%
Operating Margin
89.39%
Net Margin
104.75%
Efficiency Metrics
Revenue per Expense Ratio
9.42
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.3300000000
Balance Sheet Analysis
Current Ratio
1.23
Cash Ratio
0.38
Working Capital
$2.78M
Debt to Equity
0.40
Debt to Assets
27.44%
Equity Ratio
68.26%
Cash Flow Analysis
Operating Cash Flow Ratio
67.16%
Free Cash Flow Ratio
67.16%
CapEx to Revenue
0.00%
Dividends Paid
$13.09M
Stock Buybacks
No buybacks
Total Shareholder Returns
$13.09M
Cash Position Change
3,592.6%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
214.11%
Net Income
216.99%
EPS
213.79%
Operating Income
20.30%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
485.75%
Operating Cash Flow
-53.06%
Free Cash Flow
-53.06%
Balance Sheet Health
Assets
5.67%
Debt
0.00%
Book Value per Share
4.39%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-17.51%
Shares Outstanding
1.49%
Long Term Trends
3Y Revenue/Share
-67.18%
5Y Revenue/Share
71.85%
3Y Dividend/Share
-30.23%
5Y Dividend/Share
-37.57%